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ABSTRACT Data on incidence, prevalence and mortality of idiopathic pulmonary fibrosis (IPF) are
sparse and vary across studies. The true incidence and prevalence of the disease are unknown. In general,
the overall prevalence and incidence reported in European and Asian countries are lower than those
reported in American studies. In recent years, the epidemiological approach to IPF has been difficult for
many reasons. First, the diagnostic criteria of the disease have changed over time. Secondly, the coding
system used for IPF in administrative databases, the most common data source used to study this aspect of
the disease, has been modified in the past few years. Finally, the study design, the methodology and the
population selected in each of the studies are very different. All these aspects make comparisons among
studies very difficult or impossible. In this review, we list the main issues that might arise when comparing
different studies and that should be taken into consideration when describing the state of epidemiological
knowledge concerning this pathology.
@ERSpublications
An accurate understanding of IPF epidemiology is important; comparisons of studies must
consider their heterogeneity http://ow.ly/P5sZF
Introduction
Idiopathic pulmonary fibrosis (IPF) is a specific and progressive form of fibrotic interstitial pneumonia of
unknown cause with a severe prognosis. Median survival is estimated to be 3–5 years from the time of
diagnosis [1, 2], and the disease prognosis is unpredictable [2, 3]. IPF was considered a rare disease with
no possible therapy until a few years ago. After several negative studies, two drugs have recently been
approved for the treatment of IPF: pirfenidone and nintedanib. This has started a new era for the
management of this devastating disease [4–7]. Despite its clinical relevance, and the extensive research into
its pathophysiology and possible therapeutic approaches, IPF remains an uncommon disorder and only a
small number of studies have focused on its epidemiology. The epidemiology of IPF has not yet been
completely investigated. This is due to the relative rarity of the disease, which makes it difficult to enrol
adequately sized study samples [8, 9]. Most information on the epidemiology of IPF comes from the USA
[10–14] and Europe [15–25], where most studies have been conducted, although we also have some
information from Asian countries [26, 27].
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As highlighted in two recent systematic reviews on IPF epidemiology [28, 29], estimated mortality and
morbidity rates are highly variable. KAUNISTO et al. [28] suggested that the observed differences are
probably due to various and heterogeneous methods of investigation and not to true geographical
differences, as some authors suggest. KAUNISTO et al. [28] also give some indications of possible reasons for
the observed variability in epidemiological parameters, such as different diagnostic criteria or disease
definition. In the most recent review, published in 2015 [29], that systematically searched for all
population-based studies on incidence and mortality of IPF, the authors listed the strengths and
weaknesses of different study designs and stressed that such differences in design make it difficult to
produce global incidence and mortality estimates through meta-analysis.
Since these aspects are crucial for correctly approaching the IPF literature, in this review we list the main
issues that might arise when comparing different studies and the issues that should be taken into
consideration when describing the state of epidemiological knowledge concerning this pathology.
Methods
We integrated the systematic review of literature on IPF epidemiology carried out by KAUNISTO et al. [28]
adding studies published before January 01, 2001, and between January 09, 2012 and April 23, 2015. We
searched for “idiopathic pulmonary fibrosis” AND “epidemiology” in the MEDLINE (PubMed) and
Science Citation Index (Web of Science) databases and selected all publications reporting measures of
incidence, prevalence and mortality of IPF. We identified 22 publications fulfilling the aforementioned
criteria, 13 of which corresponded to those included in the review by KAUNISTO et al. [28]. Finally, we
added a further recent study that did not fulfil the inclusion criteria but reported the results of a German
IPF registry [30].
Results
Three commonly used methods for the evaluation of IPF epidemiology in a population have been used in
the different published studies: national registries of interstitial lung diseases (ILDs), questionnaires send to
pulmonologists and the most common method used in the IPF epidemiological studies, the use of
pre-existing databases [28]. The results published from these studies are very different (table 1).
After reviewing the 23 selected studies, we decided to distinguish between those using administrative
databases [9, 11–14, 18, 19, 24, 25, 31, 32, 34, 35] and those using clinical data [11, 13, 15, 16, 18, 20–24,
26, 27, 30, 32, 33], as they have completely different features. We then structured our review into three
parts: we will first discuss comparison issues within the group of studies based on administrative
databases, similarly we will then address the group of studies based on clinical data, and finally, we will
highlight the major challenges in comparing the two groups.
Comparability among studies based on administrative databases
Studies which used administrative databases looked at databases recording hospital admissions [11–14, 18,
19, 25, 32, 34], outpatient visits [11–14, 32, 34] and death certificates [9, 11, 24, 25, 31, 35]. While the
database on death certificates generally covers the whole population of a country or of a defined area,
information about hospitalisations and outpatient claims is usually stored to trace the healthcare
expenditures borne by insurers or national healthcare systems and consequently it could cover the whole
population or only a portion of it. Therefore, selection bias might occur in those studies concerning
countries where the national healthcare system does not provide a universal coverage or where insurance
data concerns only a portion of the population with specific characteristics (e.g. high or low socioeconomic
status). Such bias would affect the comparability of two studies based on administrative databases. For
example, one of the largest studies carried out in the USA [12] used the claim database of a large health
plan to define the incidence and the prevalence of IPF. The overall rates of prevalence were estimated
to range between 14 and 43 per 100000 person-years, while the incidence ranged between 7 and 16 per
100000 person-years, depending on the case definition. It should be noted that patients covered by the
health plan might not be representative for the whole population, because they might have a higher
socioeconomic status given that they can afford a health plan.
Furthermore, in these databases patients with IPF are identified through algorithms based on the
diagnoses reported in such archives and usually coded using the International Classification of Disease
(ICD) ninth or 10th revision (ICD-9CM or ICD-10). IPF was not given a diagnostic code in the ICD until
the ninth revision (ICD-9) at the end of the 1970s. However, selection algorithms are not homogenous;
therefore, when comparing studies of this kind we should ask ourselves if the differences in the selection
criteria can lead to the identification of samples of patients with different characteristics (e.g. different
disease severity). If we compare the study by VON PLESSEN et al. [19] with that of RAGHU et al. [14],
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TABLE 1 Studies on idiopathic pulmonary fibrosis (IPF) epidemiology
First author
[ref.]
Country and
study period
Study methods and case definition Study population Age limitations Rates per 100000 person-years
MANNINO [31] USA, 1979–1991 Source: death certificate reports compiled by the
National Center for Health Statistics
US population (N/A) None Mortality for PF: 330 (95% CI N/A)
Cases identified based on: ICD-8CM codes and
ICD-9CM codes (515, 516.3), used to identify PF
COULTAS [11] USA, 1988–1990 Source: population-based ILD registry, clinical
and administrative databases
Cases identified based on: physician diagnosis,
following a common guideline
480577 (year: 1990) ⩾18 years (stratified
data for ⩾35 years)
Prevalence of IPF:
Males 20.2 (95% CI N/A);
Females 13.2 (95% CI N/A)
Incidence of IPF:
Males: 10.7 (95% CI N/A);
Females: 7.4 (95% CI N/A)
OLSON [9] USA, 1992–2003 Source: death certificate reports compiled by the
National Center for Health Statistics
US population (N/A) None (stratified data
for ⩾45 years)
Mortality for PF: 508 (95% CI N/A)
Cases identified based on: ICD-9CM codes (515,
516.3) and ICD-10CM codes ( J84.1), used to
identify PF
RAGHU [ 12 ] USA, 1996–2000 Source: healthcare claims databases of a health
plan
Cases identified based on: ICD9-CM codes
2149054 ⩾18 years Broad case definition:
Prevalence of IPF 42.7 (95% CI N/A);
Incidence of IPF 16.3 (95% CI N/A)
(516.3), with two algorithms (broad case
definition# and narrow case definition¶)
Narrow case definition:
Prevalence of IPF 14.0 (95% CI N/A);
Incidence of IPF 6.8 (95% CI N/A)
FERNÁNDEZ PÉREZ
[13]
USA, 1997–2005 Source: clinical and administrative database of
medical care
Cases identified based on: ICD9-CM codes
(516.3), hospital international classification of
diseases-adapted codes (517, 519), physician
diagnosis, ATS/ERS consensus 2002 [37]
Two algorithms (narrow case definition+ and
broad case definition§)
∼128000 (all ages) ⩾50 years Broad case definition:
Prevalence of IPF 63.0 (95% CI 36.4–89.6);
Incidence of IPF 17.4 (95% CI 12.4–22.4)
Narrow case definition:
Prevalence of IPF 27.9 (95% CI 10.4–45.4);
Incidence of IPF 8.8 (95% CI 5.3–12.4)
RAGHU [14] USA, 2000–2011 Source: administrative claims from a 5% random
sample of Medicare beneficiaries
Cases identified based on: ICD9-CM codes
(516.3), with two algorithms (broad case
definition# and narrow case definition¶)
2871436 ⩾65 years Broad case definition:
Prevalence of IPF 82.6 (95% CI N/A) in 2001;
233.3 (95% CI N/A) in 2011
Incidence of IPF 31.1 (95% CI N/A) in 2001;
43.0 (95% CI N/A) in year 2011
Narrow case definition:
Prevalence of IPF 30.5 (95% CI N/A) in 2001;
145.7 (95% CI N/A) in 2011
Incidence of IPF 15.9 (95% CI N/A) in 2001;
31.1 (95% CI N/A) in 2011
NAVARATNAM [24] UK, 1968–2009 Source: the Health Improvement Network
database (primary care), death certificates from
the Office for National Statistics
Population of the study
area (N/A)
⩾40 years Incidence of IPF 2000–2009: 7.44 (95% CI 7.12–7.77)
Cases identified based on: ICD-8CM codes (517),
ICD-9CM codes (516.3, 515), ICD-10CM codes
( J84.1), the Read codes (H563.00, H563.11,
H563.12, H563100, H563z00)
Mortality for IPF 1968–2008: 2.54 (95% CI 2.52–2.56)
Continued
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TABLE 1 Continued
First author
[ref.]
Country and
study period
Study methods and case definition Study population Age limitations Rates per 100000 person-years
KOLEK [15] Czech Republic,
1981–1990
Source: retrospective observational study
in 24 centres
4033010 (year 1990) None Prevalence of CFA 6.5 (95% CI N/A) in 1981;
12.1 (95% CI N/A) in 1990
Cases identified based on: physician diagnosis
of CFA
Incidence of CFA 0.74 (95% CI N/A) in 1981;
1.28 (95% CI N/A) in 1990
VON PLESSEN [19] Norway, 1984–1998 Source: hospital records
Cases identified based on: ICD-8CM codes (517,
517.00, 517.01, 517.09) and ICD-9CM codes (515,
516.3, 516.8, 516.9), used to identify CFA
254999 (year 1999) ⩾16 years All CFA cases:
Prevalence 23.4 (95% CI 14.9–33.0)
Incidence 4.3 (95% CI N/A)
CFA cases after clinical validation:
Prevalence 11.4 (95% CI N/A)
Incidence 2.7 (95% CI N/A)
GRIBBIN [23] UK, 1991–2003 Source: the Health Improvement Network
database (primary care)
1555152 (all ages) ⩾40 years Incidence of IPF 4.6 (95% CI 4.3–4.9)
Cases identified based on: physician diagnosis
THOMEER [16] Belgium, 1992–1996 Source: population-based ILDs registry
in 20 centres
5768925 None Prevalence of IPF 1.25 (95% CI N/A)
Incidence of IPF 0.22 (95% CI N/A)
Cases identified based on: physician diagnosis,
ATS/ERS consensus 2000 [36]
HODGSON [18] Finland, 1997–1998 Source: pulmonary clinic databases nationwide
(29 clinics)
5170000 None Prevalence of IPF 16–18 (95% CI N/A)
Cases identified based on: ICD10-CM codes
( J84.1), physician diagnosis, ATS/ERS guidelines
2000 [36]
TINELLI [21] Italy, 1998–2005 Source: national register for ILDs, voluntary
participation
N/A None Number of IPF cases: 864, rates N/A
Cases identified based on: physician diagnosis
XAUBET [20] Spain, 2000–2001 Source: population-based ILDs registry in 23
respiratory centres
6700000 None Incidence of ILDs 7.6 (95% CI N/A)
IPF constituted 38.6% of cases
Cases identified based on: physician diagnosis,
ATS/ERS consensus 2000 [36] and 2002 [37]
HYLDGAARD [32] Denmark, 2003–2009 Source: clinical and administrative databases,
patients who were diagnosed with ILDs
Population of the study
area (N/A)
None Incidence of ILDs 4.1 (95% CI N/A)
IPF constituted 28.0% of cases
Cases identified based on: ICD10-CM codes,
validation with ATS/ERS consensus 2011 [1]
KARAKATSANI [22] Greece, 2004 Source: ad hoc questionnaires for investigating
incidence and prevalence of IPF
∼3360000 ⩾16 years Prevalence of IPF 3.38 (95% CI N/A)
Incidence of IPF 0.93 (95% CI N/A)
Cases identified based on: physician diagnosis,
ATS/ERS consensus 2002 [37]
AGABITI [25] Italy, 2005–2009 Source: hospital admissions database, mortality
database of the regional public health service
in Lazio
4727710 ⩾18 years All IPF cases:
Prevalence 25.6 (95% CI 25.1–26.2)
Incidence 7.5 (95% CI 7.3–7.7)
IPF “confident” definition after hospital chart audit:
Prevalence 31.6 (95% CI 30.9–32.2)
Incidence 9.3 (95% CI 9.2–9.4)
Cases identified based on: ICD9-CM codes (516.3)
MUSELLIM [33] Turkey, 2007–2009 Source: ad hoc questionnaires, prospective study
(31 centres in 19 cities)
N/A None Incidence of ILDs 25.8 (95% CI N/A)
IPF constituted 19.9% of cases
Cases identified based on: physician diagnosis,
ATS/ERS guidelines 2002 [37], to identify ILDs
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TABLE 1 Continued
First author
[ref.]
Country and
study period
Study methods and case definition Study population Age limitations Rates per 100000 person-years
BEHR [30] Germany, 2012–2014 Source: national register for IPF (19 centres) N/A ⩾18 years Number of IPF cases: 502
Number of prevalent IPF cases: 331
Number of incident IPF cases: 171
Rates N/A
Cases identified based on: physician diagnosis
LAI [34] Taiwan, 1997–2007 Source: administrative databases from Bureau of
National Health Insurance and Ministry of the
Interior, regarding health services and deaths
2619534 (all ages) ⩾18 years Broad case definition:
Prevalence of IPF 0.7 (95% CI N/A) in 1998;
6.4 (95% CI N/A) in 2007
Incidence of IPF 0.6 (95% CI N/A) in 1998;
1.4 (95% CI N/A) in 2007
Cases identified based on: ICD9-CM codes
(516.3), with two algorithms (broad case
definition# and narrow case definition¶) Narrow case definition:
Prevalence of IPF 0.5 (95% CI N/A) in 1998;
4.9 (95% CI N/A) in 2007
Incidence of IPF 0.5 (95% CI N/A) in 1998;
1.2 (95% CI N/A) in 2007
NATSUIZAKA [27] Japan, 2003–2007 Source: clinical database of patients with IPF and
the Certificate of Medical Benefit
5572770 None Prevalence of IPF 10 (95% CI N/A)
Incidence of IPF 2.23 (95% CI N/A)
Cases identified based on: physician diagnosis,
ATS/ERS guidelines 2000 [36]
OHNO [26] Japan, 2005 Source: clinical database of patients with IIP and
the Certificate of Medical Benefit
127756815 None Prevalence of IIP 3.44 (95% CI N/A)
Number of IPF prevalent cases: 1322
Number of IPF incident cases: 545Cases identified based on: physician diagnosis
HUTCHINSON [35] Worldwide, 1999–2012 Source: mortality data from national statistics
agencies
N/A None Mortality for IPF 2010 J84: between 4.60
(Sweden) and 9.93 ( Japan) (95% CI N/A)
J84.1: between 4.63 (Spain) and 7.19
(England and Wales) (95% CI N/A)
Cases identified based on: ICD10-CM codes
( J84 and J84.1)
ICD: International Classification of Diseases; PF: pulmonary fibrosis; N/A: not available; ILD: interstitial lung disease; ATS: American Thoracic Society; ERS: European Respiratory
Society; CFA: cryptogenic fibrosing alveolitis; IIP: idiopathic interstitial pneumonia. #: age ⩾18 years, at least one medical claim with a diagnosis code for IPF (ICD-9-CM 516.3), no
medical claims with a diagnosis code for any other ILDs on or after the date of the last medical claim with a diagnosis code for IPF; ¶: met broad case definition (see #) plus had at least
one medical claim with a procedure code for surgical lung biopsy, transbronchial lung biopsy or high-resolution computed tomography (HRCT) on or before the date of the last medical
claim with a diagnosis code for IPF; +: usual interstitial pneumonia (UIP) on surgical lung biopsy specimen or a definite UIP pattern on a HRCT image; §: UIP on surgical lung biopsy
specimen or a definite or possible UIP pattern on a HRCT image.
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we should keep in mind that the first study selected all diagnoses coded as 515, 516.3, 516.8 and 516.9
(ICD9-CM) as potential IPF cases, while the second study focused on 516.3.
While it is likely that studies using different ICD codes to detect IPF will lead to the selection of
nonhomogeneous patients, even if the ICD codes are the same the accuracy of the reported diagnosis or
cause of death might vary across different geographical areas or even within the same area. The accuracy
of the reported diagnosis depends on the background of the physician who registered the diagnosis: using
this data source, it is impossible to ascertain whether this physician was a pneumologist or not. The
accuracy also depends on the study period, as diagnostic procedures have greatly improved in recent
decades making diagnosis more and more precise. In particular, the introduction and spread of
high-resolution computed tomography (HRCT) has completely changed IPF diagnosis. During the 1990s,
HRCT scans became routine in the evaluation of patients with ILD. As the technology advanced, HRCT
proved to be a simple, noninvasive, relatively inexpensive method (compared with surgical lung biopsy) to
make a confident diagnosis of IPF in many patients. The role of bronchoalveolar lavage and transbronchial
biopsy in IPF diagnosis has also changed over time and the relevance of these two methodologies has been
revisited in the latest statement from the American Thoracic Society (ATS)/European Respiratory Society
(ERS)/Japanese Respiratory Society/Latin American Thoracic Association [1].
Another factor that can cause differences over time and affect the comparability among studies is the
introduction and evolution of guidelines to identify ILD in general, and more specifically IPF. A first
consensus statement for the diagnosis and the management of IPF was published in 2000 [36] and was
then revised in 2011 [1]. These statements have determined a more precise definition of the radiological
and histological diagnosis of IPF than before. Changes in classification of idiopathic interstitial
pneumonias (IIP) and diagnostics make comparison between studies conducted in different decades
difficult [36, 37]. For example, it is hard to compare estimated incidence and prevalence rates from a study
based on the adult population in Bernalillo County, NM, USA in 1988–1990 [11], i.e. 10 years before the
first consensus statement, with those of a more recent study carried out after the first consensus statement
in the USA from 2001 to 2011 [14].
In addition to this, one should also look at when the guidelines were actually introduced into clinical
practice: the gap between first publication and the actual adoption of these guidelines can be different
among countries, but also within the same country. Therefore, even studies carried out in the same period
might gather cases diagnosed following different guidelines. This might also affect estimates of the
temporal trends within the same study, for example in Olmsted County, MN, USA [13] during the period
1997–2005, using a broad case definition, incidence ranged between 24.6 per 100000 person-years during
the period 1997–1999 and 11.0 per 100000 person-years during the period 2003–2005. We should keep in
mind that the observed decrease might be due to the introduction of the first ATS/ERS consensus
statement [36]. A similar observation applies to a study conducted in Taiwan during the period 1997–2007
[34]. Another important feature that should also be considered is the presence of a clinical validation of
the diagnosis reported in the administrative archives: not all of the studies ascertain the diagnosis through
a clinical revision of each patient’s medical record. The proportion of patients wrongly classified as IPF
cases is likely to be higher in studies lacking a validation. Studies that determined the cases with a clinical
validation usually integrated administrative and clinical databases [11, 13, 18, 19, 32].
Even with clinical validation, in the case of administrative databases it is difficult to go back to the true
disease onset. We can assume that the onset corresponds to the first access of healthcare services, but
different cultural and economic reasons might lead the IPF patient to seek medical care at different stages
during the clinical course of the disease.
Moreover, studies which only use hospital admission databases cannot detect those patients who are
followed solely through outpatient visits and who are never hospitalised (e.g. those who die before their
first hospitalisation). This affects the comparison between studies which considered both outpatient and
inpatient claims [11–14, 32, 34] and those which focused only on inpatient claims [18, 19, 25].
If we again focus on the identification of disease onset, it should be noted that some patients might have
accessed healthcare services with an IPF diagnosis before the study period; therefore, studies that use a
washout period probably produce less biased estimates of incidence and prevalence than those that don’t
consider this issue. For example, RAGHU et al. [14] required a washout period of 1 year before the first
available diagnosis of IPF, unlike VON PLESSEN et al. [19] who did not make any restrictions. Also the
length of the washout period might affect the estimates.
Last but not least, there are some methodological aspects regarding rate calculations that are crucial when
wanting to compare estimated rates. First, since it has been shown that age and gender are risk factors for
IPF and that the demographic structures of the populations involved in the studies might be different, a
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proper comparison should aim to standardise the results [38], although this is possible only if the authors
provide age- and gender-specific rates, using the same age classes. For example, we should be careful when
comparing the estimates from Bernalillo County [11] and Olmsted County [13]. Although they both
provide age- and gender-specific rates, they use different age-classes. Both studies use 10-year-wide classes,
but the first study starts at 35 years of age, while the second starts at 50 years of age. In addition, it is
advisable to provide a variability measure (standard error or confidence interval) of the estimated rates,
because this allows reliable statistical comparisons to be built. Finally, if we are comparing overall rates we
should always verify if the studies applied different age limits to the study population: the overall rates
estimated in the US Medicare population [14] are not directly comparable to those estimated within a US
population covered by a health plan [12], because the first study involves only patients aged 65 years and
older, while the second also involves younger patients (⩾18 years of age).
Comparability among studies based on clinical databases
In the second group of studies, based on clinical databases, we included all national registries of ILDs,
studies with questionnaires where data collection was based on the activity of physicians [15, 16, 20–22,
27, 30, 33] and studies based on existing clinical databases, such as The Health Improvement Network in
the UK [24, 26, 32].
In these studies, the quality of the collected data relies on the background information received from the
different physicians, on the ATS/ERS guidelines used at the time of the study and on the available
diagnostic procedures. Given that these features can vary over time, we should be careful when comparing
studies carried out in different years, such as the Greek study [22] that identified IPF cases in 2004
according to the ATS/ERS guidelines of 2000 [36] and the registry built in Flanders [16], that did not
follow a guideline as it identified cases during the period 1992–1996.
Furthermore, physicians who take part in registries and questionnaire-based studies are volunteers. This
could generate a selection bias: differences in the activity of the physicians in reporting patient numbers
and data might lead to the selection of a sample of patients that is not representative of the whole
population and, consequently, to the estimation of nongeneralisable epidemiological parameters. As
reported by KAUNISTO et al. [28], it is essential to know the extent and demographic structure of the
population covered by registries or assisted by the physicians, in order to properly estimate the
denominator for the epidemiological calculations. As mentioned previously, demographic structures also
affect comparability among estimates, and therefore, authors should provide age- and gender-specific rates,
in order to standardise the results.
From a statistical point of view, once again, comparisons would require a variability measure for the
estimated rates. Finally, age limitations should be carefully checked.
Studies based on clinical databases versus studies based on administrative databases
To conclude this review, we would like to describe further issues that might complicate the comparison
between studies which use administrative and clinical data.
First of all, the disease onset estimated in studies based on administrative databases is likely to be further
from the real one, as opposed to that estimated in the other group of studies. Therefore, the age
distribution of incident cases might differ in the two groups of studies due to the study design. For
example, age at onset might be systematically lower in clinical studies, because IPF patients access
inpatient or outpatient services after the first physician diagnosis. In addition to this, clinical studies
identify patients at the first diagnosis made by the physician [15, 16, 21–23, 27, 33], while studies based on
administrative data identify the patient at his or her first outpatient or inpatient claim [12, 14, 19, 25, 34].
If a subject has no such claims, this results in an underestimation of the number of incident cases in
studies based on administrative data.
Finally, the ATS/ERS guidelines used to identify the patient are usually stated in clinical studies [20, 22, 27,
33], while they are unknown in studies based on administrative databases, because, as previously
mentioned, it is impossible to know when each guideline was actually implemented. This inevitably leads
to the selection of nonhomogenous patients.
Discussion
In this review we have outlined the differences in the various studies on IPF epidemiology. We tried to
understand if the differences in results between studies are true differences or if they actually come from
the different methodologies used or are due to the difficulty in comparing results in this type of study. The
relative rarity of IPF has constituted a challenge for investigators with an interest in its epidemiology and,
before 1990, it had discouraged the performance of large scale epidemiological studies [8]. The study of
442 DOI: 10.1183/16000617.0040-2015
RARE PULMONARY DISEASES AND ORPHAN DRUGS | A. CAMINATI ET AL.
epidemiology in IPF has been difficult for many other reasons. First, the definition of the disease has
changed over time. Secondly, the diagnosis codes used to identify IPF in the administrative databases, the
most common approach used in IPF epidemiology studies, has also changed over time. Moreover, the
ICD-9-CM code 516.3 is not specific for IPF and may include other IIPs, such as nonspecific interstitial
pneumonia or acute interstitial pneumonia. For studies based on administrative databases, it should be
stressed that such databases are not universally available or easy to access for epidemiological analyses. For
example, in some countries legal issues might impede the use of health administration data for research
purposes.
The differences that exist between studies, regarding the methodology employed for the determination of
incidence and prevalence of IPF, make comparison very difficult. The result of this situation is that the
true incidence and prevalence of IPF cannot be properly established, as they vary across studies [39]. In
recent years, more studies have been published which focus on epidemiology of IPF in Europe, USA and
Asian countries and, despite the differences between studies, some important information has been
acquired.
IPF is a disease of older age and is prevalent in males. All the epidemiological studies agree on this aspect
of the disease [11–14, 21, 23–25, 27, 33, 34] and confirm the results from clinical studies [4–7]. The only
exception was the study conducted in Norway, where 55% of the incident cases were women. Norwegian
women were amongst the heaviest smokers in the world and smoking is known to be risk factor for the
development of IPF, so this may explain the predominance of females observed in this study [19].
The mean survival of an IPF patient is 3–5 years from different studies [13, 14].
Generally, the prevalence and incidence of IPF are higher in American studies [11–14] than in European
[15, 16, 18–20, 22–25, 32] and Asian studies [26, 27, 34]. Although it is unclear whether this is due to true
differences in geographic and ethnic aspects or simply due to methodological differences in the way the
studies were conducted (as discussed earlier).
Generally, studies based on administrative databases involve a larger population but data re-evaluation and
validation is more difficult, when compared with studies based on clinical data that involve a smaller
group of patients but with more controlled data.
There seems to be geographic variability in IPF epidemiology because some differences have been observed
across regions using similar methodologies [18, 23, 24]. These differences may be due to environmental
exposure or ethnic background [40–42]. For example, important differences have been observed in the
causes of death between a recent Japanese study and American studies. In the Japanese study, a total of
328 patients (59.3% of patients with IPF) died from various causes. Focusing on the sample of patients
with IPF, the most common cause of death was an acute exacerbation of the disease (40% of the events),
followed by lung cancer (11%), pneumonia (7%) and cardiovascular diseases (3%) [27]. The percentage of
acute exacerbations was higher than in American studies [9, 13, 31, 43] and the authors suggested an
ethnic difference, particularly between East Asian and Western populations.
In conclusion, epidemiological estimates from different studies cannot be directly compared without taking
their heterogeneity into consideration and keeping in mind the numerous intervening elements. However,
it is clear that an accurate understanding of the epidemiology of IPF is important in order to estimate the
size of the problem. The existence of uniform, international diagnostic guidelines for a definitive IPF
definition and of a clear systematic classification code system enables the collection of more accurate and
comparable data in the future.
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